Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.

Stephanie Yaung,Liu Xi,Corinna Woestmann,Sylvie McNamara,Bernd Hinzmann,Sebastian Fröhler,Nalin Tikoo,Christine Ju,Aarthi Balasubramanyam,Patrik Vitazka,Amrita Pati,Alexander F. Lovejoy,Daniel M. Klass,Hans-Peter Adams,Michael Thomas,Felix Herth,Thomas Muley,Birgit Wehnl,John F. Palma,Xiaoju Max Ma

Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.

2018

12045Background: Studies show that mutation count can be used as a biomarker to predict whether or not a patient may respond to immunotherapy or chemoradiation therapy. However, mutation count is u...

Keywords:

Circulating tumor DNA
Cell
Lung
Cancer research
Pathology
Lung cancer
Mutation
Adenocarcinoma
Medicine
late stage
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations